Wong, Kin Yau
Fan, Cheng
Tanioka, Maki
Parker, Joel S.
Nobel, Andrew B.
Zeng, Donglin
Lin, Dan-Yu
Perou, Charles M. http://orcid.org/0000-0001-9827-2247
Funding for this research was provided by:
National Cancer Institute (P50-CA58223–09A1)
Breast Cancer Research Foundation
Susan G. Komen
V Foundation for Cancer Research
National Institutes of Health (R01CA148761)
National Institutes of Health (R01GM047845)
National Institutes of Health (R01HG009974)
National Institutes of Health (P01CA142538)
Article History
Received: 15 May 2018
Accepted: 23 January 2019
First Online: 7 March 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: CMP is an equity stock holder, consultant, and Board of Director Member of BioClassifier LLC and GeneCentric Diagnostics. CMP is also listed as an inventor on patents on the Breast PAM50 and Lung Cancer Subtyping assays. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.